Chief executive Nikhil Rathi said the changes are ‘a risk worth taking, allowing more people the security that comes with ...
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback